MNC x Startup Innovation Merck and Predicine

Join our discussion on Tuesday, 25th June with Dr. Sean Zeng, Sr. Manager of Cross-Sector Innovation Collaboration at Merck, Dr. Shichun Tu, CEO of Huidu (Shanghai) Medical Sciences from Predicine and Dr. Qihui Shi, professor at Fudan University Shanghai Medical College. We will discuss various topics in liquid biopsy e.g. front-end enabling technologies, current workflow bottlenecks, and applications beyond cancer, etc. We will also explore why VCs have been chasing and betting large sums in this technology. Predicine has successfully raised Series A Round in 2018 from reputable VCs.

我们有幸邀请到默克集团的跨领域创新合作高级经理曾思禹博士、慧渡医疗（上海）的CEO涂士春博士和复旦大学上海医学院生物医学研究院教授施奇惠博士，在6月25日周二晚，一起探讨液体活检技术相关的各种主题，例如前沿赋能技术、当前工作流程中的瓶颈、癌症以外的应用等。以及为何风投一直追逐并大额投资该技术。慧渡医疗于去年成功完成近亿元A轮融资。